Atai Beckley, Inc. (ATAI)
4.94
+0.36
(+7.86%)
USD |
NASDAQ |
Jun 26, 14:12
Atai Beckley Cash from Operations (TTM) : -109.14M for March 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -109.14M |
| December 31, 2025 | -105.89M |
| September 30, 2025 | -77.84M |
| June 30, 2025 | -69.32M |
| March 31, 2025 | -76.59M |
| September 30, 2024 | -79.85M |
| June 30, 2024 | -78.28M |
| March 31, 2024 | -85.14M |
| December 31, 2023 | -83.67M |
| Date | Value |
|---|---|
| September 30, 2023 | -94.28M |
| June 30, 2023 | -100.69M |
| March 31, 2023 | -98.52M |
| December 31, 2022 | -101.39M |
| September 30, 2022 | -88.80M |
| June 30, 2022 | -91.27M |
| March 31, 2022 | -68.62M |
| December 31, 2021 | -61.16M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Definium Therapeutics, Inc. | -145.05M |
| GH Research Plc | -47.01M |
| Johnson & Johnson | 22.87B |
| Eli Lilly & Co. | 20.48B |
| Nektar Therapeutics | -203.76M |